Anonymous
Guest
Anonymous
Guest
By Zurich Bureau
ZURICH -(MarketWatch)- Novartis AG /quotes/zigman/171707/quotes/nls/nvs NVS -0.05% , Europe's largest pharmaceutical company by sales, has no plans for any large acquisitions in the next two years, Chief Executive Joe Jimenez said in an interview published in the TagesAnzeiger newspaper Tuesday.
"With the purchase of Alcon we have increased our debt [level] considerably, and this needs to be repaid," Jimenez is quoted as saying in an online edition of the newspaper.
"We are talking here of foreign capital of $17 billion.
TRANSALATION- WE ARE SCREWED !
NO MONEY TO REPAY OUR DEBT BECAUSE OF THE PATENT CLIFF ,
LOSS OF ALISKREN & UNDERWHELMING OTHER PRODUCTS IN OUR CRAPPY
PORTFOLIO COUPLED WITH A CIPHER PHANTOM PIPELINE
ZURICH -(MarketWatch)- Novartis AG /quotes/zigman/171707/quotes/nls/nvs NVS -0.05% , Europe's largest pharmaceutical company by sales, has no plans for any large acquisitions in the next two years, Chief Executive Joe Jimenez said in an interview published in the TagesAnzeiger newspaper Tuesday.
"With the purchase of Alcon we have increased our debt [level] considerably, and this needs to be repaid," Jimenez is quoted as saying in an online edition of the newspaper.
"We are talking here of foreign capital of $17 billion.
TRANSALATION- WE ARE SCREWED !
NO MONEY TO REPAY OUR DEBT BECAUSE OF THE PATENT CLIFF ,
LOSS OF ALISKREN & UNDERWHELMING OTHER PRODUCTS IN OUR CRAPPY
PORTFOLIO COUPLED WITH A CIPHER PHANTOM PIPELINE